Vendor, Morrisville, NC
Locus Biosciences Inc.
UEI CJKVLKZGX6F3, CAGE 7H2T2
2 awards and $61,993,217 obligated between January 19, 2024 and October 16, 2026, 100% under full and open competition, against 8.5 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $48,826,300 |
| National Institutes of Health | $13,166,917 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $61,993,217 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Hear when Locus Biosciences Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Locus Biosciences Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $48,826,300
- Soonest
- January 1, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to Office of Assistant Secretary for Preparedness and Response, by dollars.
| Advanced Technology InternationalSummerville, SC | $2,764,576,471 |
| Albert B. Sabin Vaccine Institute, Inc. (The)Washington, DC | $356,898,734 |
| Amgen USA Inc.Thousand Oaks, CA | $345,705,117 |
| Start2 Group, Inc.Cambridge, MA | $227,139,021 |
| Siga Technologies, Inc.New York, NY | $177,835,284 |
| Shionogi Inc.Florham Park, NJ | $156,109,904 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50120C00169Definitive Contract, January 19, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purposes of This Modification Are to 1. Exercise Option Period 1 Clin 0002 with a Period of Performance of January 19, 2024 to SeptemberNAICS 541714, PSC AN13 | $48,826,300 |
| 75N93025C00035Definitive Contract, September 22, 2025, Full and Open Competition, 16 offers | National Institutes of Health NiaidNational Institutes of Health | Advance a Novel Therapeutic to a First-In-Human Clinical StudyNAICS 541714, PSC AN12 | $13,166,917 |
- Places of performance
- North Carolina
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 9 across 2 awards